Hikma Pharmaceuticals Plc (OTCMKTS:HKMPF - Get Free Report) shares gapped down prior to trading on Wednesday . The stock had previously closed at $27.96, but opened at $26.38. Hikma Pharmaceuticals shares last traded at $26.38, with a volume of 200 shares changing hands.
Analyst Ratings Changes
Separately, BNP Paribas started coverage on Hikma Pharmaceuticals in a research note on Tuesday, May 13th. They issued an "outperform" rating on the stock.
Get Our Latest Report on Hikma Pharmaceuticals
Hikma Pharmaceuticals Stock Performance
The stock's 50 day moving average is $27.65 and its 200 day moving average is $27.03. The company has a quick ratio of 0.65, a current ratio of 1.14 and a debt-to-equity ratio of 0.28.
About Hikma Pharmaceuticals
(
Get Free Report)
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.
Featured Stories
Before you consider Hikma Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hikma Pharmaceuticals wasn't on the list.
While Hikma Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.